Skyrizi Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The skyrizi market research report is one of a series of new reports that provides skyrizi market statistics, including skyrizi industry global market size, regional shares, competitors with a skyrizi market share, detailed skyrizi market segments, market trends and opportunities, and any further data you may need to thrive in the skyrizi industry. This skyrizi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing adoption in psoriasis, increasing number of patients, growing geriatric population, increasing awareness and improved diagnosis, and increased consumption of processed foods. Major trends in the forecast period include technological innovations in biologics, a shift toward combination therapies, advancements in diagnostic technologies, a shift from oral to injectable treatments, and artificial intelligence (AI) for drug development.

The increasing prevalence of psoriasis is expected to drive the growth of the Skyrizi market. Psoriasis is a chronic autoimmune condition that leads to the rapid buildup of skin cells, causing scaling on the skin's surface. Factors such as genetic predisposition, environmental triggers, greater awareness, improved diagnosis rates, lifestyle changes, and the rising impact of stress and immune-related disorders contribute to the growing prevalence of psoriasis. Skyrizi, a biologic therapy that targets interleukin-23 (IL-23), treats psoriasis by blocking this cytokine, which plays a crucial role in the inflammatory process. This reduces skin inflammation, alleviates symptoms such as redness and scaling, and improves overall skin clearance in patients with moderate to severe plaque psoriasis. For example, the National Psoriasis Foundation reported in December 2022 that around 8 million Americans and 125 million people worldwide have psoriasis, with 30% of them also developing psoriatic arthritis. As the prevalence of psoriasis increases, the demand for Skyrizi is expected to rise.

The growing interest in personalized medicine is anticipated to further fuel the growth of the Skyrizi market. Personalized medicine is an approach that tailors treatments and healthcare strategies to the individual characteristics of each patient, including their genetic makeup, environment, and lifestyle, to achieve the most effective outcomes. The rising adoption of personalized medicine is driven by advancements in genomics, an improved understanding of molecular biology, the availability of precision diagnostic tools, and the demand for targeted therapies that enhance patient outcomes and minimize side effects. Skyrizi supports personalized medicine by providing a biologic therapy that specifically inhibits IL-23, allowing healthcare providers to tailor treatments for patients with moderate to severe autoimmune diseases such as psoriasis and ulcerative colitis. This targeted approach improves treatment efficacy while minimizing side effects. In 2023, the Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare disease patients, a significant increase from the six approvals in 2022. As the focus on personalized medicine grows, the Skyrizi market is expected to expand.

The key trend in the skyrizi market is the expansion of its therapeutic indications, such as for ulcerative colitis (UC), which enhances treatment options for autoimmune diseases. Skyrizi has been approved for the treatment of moderate-to-severe UC, showing promising clinical improvements in patients who have not responded to other therapies. For example, in July 2024, AbbVie received approval from the European Commission for Skyrizi to treat adult patients with moderately to severely active UC who have not responded to or are intolerant of conventional or biologic therapies. This approval followed positive results from Phase 3 trials, including INSPIRE and COMMAND, which demonstrated mucosal healing in patients who had not previously used biologic or JAK inhibitor therapies. Skyrizi’s dosing regimen includes a 1,200 mg induction dose followed by maintenance doses of 180 mg or 360 mg every 8 weeks. This expansion of indications offers new hope for UC patients who have not found success with conventional treatments.

The key company operating in the skyrizi market is AbbVie Inc.

North America was the largest region in the skyrizi market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in skyrizi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the skyrizi market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Skyrizi is a prescription medication used to treat certain autoimmune conditions, including moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn's disease, by reducing inflammation in the body. The mechanism of action of Skyrizi (risankizumab-rzaa) involves selectively targeting and inhibiting interleukin-23 (IL-23), a protein that plays a key role in inflammatory and immune responses.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for skyrizi include plaque psoriasis, Crohn's disease, and ulcerative colitis. Plaque psoriasis is a common form of psoriasis characterized by raised, red patches covered with silvery-white scales, typically appearing on the scalp, elbows, and knees. This condition causes discomfort and irritation for affected individuals. Skyrizi is available in formulations such as pre-filled syringes and vials and is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The skyrizi market consists of sales of intravenous (IV) infusion for induction and subcutaneous (SC) injection and pen injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.